secwatch.observer — SEC 8-K summary
======================================

Issuer:     Day One Biopharmaceuticals, Inc. (—)
CIK:        0001845337
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001193125-24-149895
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Day One sells Rare Pediatric Disease PRV for $108M; $8.1M to Viracta
--------------------------------------------------------------------

- Closed sale of Priority Review Voucher for $108M in cash on May 29, 2024.
- PRV awarded after FDA accelerated approval of OJEMDA (tovorafenib) on April 23, 2024.
- $8.1M of proceeds will be paid to Viracta to fully satisfy PRV-related obligations.
- Proceeds provide non-dilutive capital to fund OJEMDA launch and clinical development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/0001193125-24-149895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845337/000119312524149895/d834662d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-149895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer